NAPLEX Diabetes Medication Practice Questions with Answers

Concept Explanation

NAPLEX diabetes medication questions focus on the pharmacotherapy of type 1 and type 2 diabetes mellitus, emphasizing drug mechanisms, adverse effect profiles, contraindications, and clinical management strategies as outlined by the American Diabetes Association. Mastering these concepts requires understanding the therapeutic hierarchy of antihyperglycemic agents, including insulin analogs, biguanides, SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors. Clinicians must apply knowledge of cardiovascular risk reduction and renal dosing adjustments to select appropriate agents for patients with comorbid conditions like chronic kidney disease or heart failure.

Solved Examples

1. Question: A 55-year-old patient with type 2 diabetes and heart failure (HFrEF) is currently on metformin. Which agent should be added to provide both glycemic control and a mortality benefit in this patient?
   Solution:
   1. Identify the patient's comorbidities: HFrEF.
   2. Review guidelines for SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin), which are indicated for HFrEF to reduce hospitalization and mortality.
   3. The correct choice is an SGLT2 inhibitor.
2. Question: Calculate the total daily dose (TDD) of insulin for a patient weighing 80 kg using a starting dose of 0.5 units/kg/day.
   Solution:
   1. Formula: $\ \text{TDD} = \ \text{Weight (kg)} \ \times \ \text{Dose (units/kg/day)}$
   2. Calculation: $80 \ \text{ kg} \ \times 0.5 \ \text{ units/kg/day} = 40 \ \text{ units/day}$
   3. Result: 40 units per day.
3. Question: Which class of diabetes medication is associated with a risk of euglycemic ketoacidosis?
   Solution:
   1. Review adverse effects of common classes.
   2. SGLT2 inhibitors block glucose reabsorption in the proximal tubule, which can sometimes lead to starvation-like states in the body, triggering ketoacidosis even with normal blood glucose levels.
   3. The correct class is SGLT2 inhibitors.

Practice Questions

1. A patient with a history of medullary thyroid carcinoma should avoid which class of diabetes medications?
2. What is the primary mechanism of action of pioglitazone?
3. A patient develops a urinary tract infection while taking canagliflozin. Is this a common side effect of this medication class?

4. Which insulin analog has the longest duration of action, typically lasting up to 42 hours?
5. Explain the rationale for using GLP-1 receptor agonists in patients with established ASCVD.
6. Calculate the insulin sensitivity factor (ISF) for a patient on 50 units of total daily insulin using the "1800 rule" for rapid-acting insulin.
7. Why should metformin be discontinued prior to the administration of iodinated contrast media?
8. Identify the drug class that carries a warning for potential bone fractures and bladder cancer.
9. A patient on canagliflozin presents with a foot ulcer. What is the black box warning associated with this drug class?
10. How does the mechanism of DPP-4 inhibitors differ from GLP-1 receptor agonists?

Answers & Explanations

1. Answer: GLP-1 Receptor Agonists. These agents carry a boxed warning regarding the risk of thyroid C-cell tumors based on rodent studies and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma.
2. Answer: PPAR-gamma agonist. Pioglitazone increases peripheral insulin sensitivity by activating peroxisome proliferator-activated receptor-gamma.
3. Answer: Yes. SGLT2 inhibitors increase glucose excretion in the urine (glycosuria), which creates an environment conducive to mycotic genital infections and UTIs.
4. Answer: Insulin degludec (Tresiba). It is an ultra-long-acting basal insulin with a half-life that allows for once-daily dosing with high flexibility.
5. Answer: Several GLP-1 RAs (like liraglutide, semaglutide, and dulaglutide) have demonstrated significant reductions in Major Adverse Cardiovascular Events (MACE) in clinical trials, making them preferred agents for patients with high cardiovascular risk.
6. Answer: Using the 1800 rule: $1800 / 50 = 36$. The ISF is 36 mg/dL per unit of insulin.
7. Answer: Metformin increases the risk of lactic acidosis if acute kidney injury occurs following contrast administration. It should be held for 48 hours post-procedure.
8. Answer: Thiazolidinediones (TZDs). Pioglitazone is associated with increased bone fracture risk and, historically, concerns regarding bladder cancer.
9. Answer: Lower limb amputation. Canagliflozin carries a FDA boxed warning for an increased risk of leg and foot amputations.
10. Answer: GLP-1 RAs are injectable analogs that provide supraphysiological levels of GLP-1 activity, whereas DPP-4 inhibitors prevent the breakdown of endogenous GLP-1, leading to modest, physiological increases.

1. Which diabetes medication class is most likely to cause hypoglycemia when used as monotherapy?

• ABiguanides
• BSulfonylureas
• CDPP-4 Inhibitors
• DSGLT2 Inhibitors

Frequently Asked Questions

Why is metformin considered the first-line therapy for type 2 diabetes?

Metformin is highly effective at lowering A1c, has a low risk of hypoglycemia, is weight-neutral or promotes mild weight loss, and is cost-effective. These factors, combined with its long-term safety profile, make it the standard initial treatment.

How do I manage a patient on insulin who is NPO for surgery?

Patients typically require a reduction in their basal insulin dose (often by 50-75%) and the holding of prandial insulin while NPO. Blood glucose must be monitored frequently to prevent hypoglycemia during the fasting period.

What is the difference between basal and bolus insulin?

Basal insulin, such as glargine or detemir, provides steady, background insulin levels throughout the day to suppress hepatic glucose production. Bolus insulin, such as lispro or aspart, is taken at mealtimes to manage postprandial glucose spikes.

Are there specific renal considerations for SGLT2 inhibitors?

Yes, SGLT2 inhibitors have dose-dependent efficacy and are generally not recommended for patients with an eGFR below 30 mL/min/1.73m². Their glucose-lowering effect diminishes as renal function declines.

Can GLP-1 receptor agonists be used in combination with insulin?

Yes, GLP-1 receptor agonists are often used in combination with basal insulin to improve glycemic control and mitigate the weight gain and hypoglycemia risk associated with insulin intensification. This combination is highly effective for many patients.